Though GSK has put considerable effort into developing pharmacological treatments for gynecological cancers—including Zejula, ...
GSK acquired Zejula as part of its $5.1 billion takeover of Tesaro in 2018, along with other oncology drug candidates, including latecomer PD-1 inhibitor Jemperli (dostarlimab) and others ...
led by PARP inhibitor Zejula (niraparib) for ovarian cancer. GSK has now revised its sales growth forecast for 2024 upwards to 7%-9% – up from 5%-7% – and now expects earnings per share growth ...
The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...
Teva Pharmaceutical Industries Ltd. ADR-2.23% $19.91B ...
CNW/ - DRI Healthcare Trust (TSX: DHT.UN) (TSX: DHT.U) ("DRI" or "the Trust") today announced its financial results for the ...
GlaxoSmithKline Pharmaceuticals Ltd. key Products/Revenue Segments include Pharmaceuticals, Service Income and Other Operating Revenue for the year ending 31-Mar-2024.For the quarter ended 30-09-2024, ...
Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.
As of November 08, 2024, GSK plc had a $73.1 billion market capitalization, putting it in the 96th percentile of companies in the Pharmaceuticals industry. Currently, GSK plc’s price-earnings ratio is ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback